-
Previous
GAL4-DBD-RXRα-LBD-BSD
$595.00 – $2,395.00
-
Next
GAL4-DBD-PPARα-LBD-BSD
$595.00 – $2,395.00
GAL4-DBD-AR-LBD-BSD
$595.00 – $2,395.00
Androgen Receptor (AR), encoded by the NR3C4 gene is a crucial steroid hormone nuclear receptor that mediates the physiological actions of androgens such as testosterone and dihydrotestosterone. It plays essential roles in the development and maintenance of reproductive tissues, muscle, bone, and various metabolic processes.
AR expression is prominent in androgen-responsive tissues, contributing to the regulation of genes that drive male characteristics, muscle growth, and reproductive health. Upon binding its hormone ligand, the AR dissociates from accessory proteins, translocates to the nucleus, and activates transcription of androgen-responsive genes, crucial for studies in oncology and endocrinology.
The GAL4-DBD-AR LBD fusion construct offers a specialized system for evaluating ligand interactions with AR. Supplied as high-titer lentiviral particles and featuring multiple readout options (GFP, RFP, or Firefly Luciferase), this product allows researchers to establish their own cell lines, avoiding repeated transfections—yielding significant cost savings and consistent experimental outcomes. For custom solutions featuring alternative nuclear receptor family members, we offer similar pricing and a streamlined production timeline.
Contact us today to see how this tool can accelerate your drug discovery pipeline and therapeutic research.
Available Options:
Specifications
Details
How It Works
The GAL4-DBD-AR-LBD-BSD construct is designed to measure the activity of the Androgen Receptor (AR), a ligand-dependent nuclear receptor that plays a critical role in regulating genes associated with the development and maintenance of reproductive and muscle tissues, as well as metabolic pathways. This construct incorporates a fusion of the GAL4 DNA-binding domain (DBD), the AR ligand-binding domain (LBD), and a BSD selection marker. The GAL4 DBD targets a specific DNA sequence in the 5x GAL4 UAS-TAG-Puro construct, which contains a reporter gene (GFP) upstream of the UAS sequence. When the AR-LBD is activated by its ligand (testosterone), the GAL4-DBD-AR-LBD fusion protein binds to the UAS sequence, resulting in transcriptional activation of the reporter gene. This setup provides a straightforward and measurable readout of AR activity via GFP fluorescence.
For added versatility in reporter detection, the GAL4-DBD-AR-LBD-BSD construct can be paired with the GAL4-TAR-Puro construct (which uses RFP as the reporter) or the GAL4-TAL-Puro construct (utilizing Firefly Luciferase as the reporter), depending on the experimental needs.
Experimental Data and Interpretation
HEK293 cells were co-transfected with GAL4-DBD-AR-LBD-BSD and GAL4-TAG-Puro constructs. After 16 hours, cells were treated with either DMSO (control) or 10 nM testosterol (ligand) in 10% FBS culture medium and incubated for an additional 16 to 24 hours. The experimental results under each condition demonstrate AR’s behavior:
- DMSO (Control): Cells treated with DMSO show baseline GFP fluorescence, indicating minimal or no transcriptional activation in the absence of ligand. This serves as a control reference level to compare against ligand-induced activity.
- 10nM Testosterone (Ligand): Treatment with testosterone activates the AR-LBD, promoting its binding to the UAS sequence and leading to robust GFP expression. This heightened fluorescence demonstrates the ligand-dependent transcriptional activation of the reporter gene, highlighting the construct’s responsiveness to androgenic signals.
This clear ligand-dependent fluorescence provides a reliable indicator of AR activity and validates the effectiveness of the GAL4-DBD-AR-LBD system in detecting androgen receptor activation.
Application and Research Utility
This construct offers researchers a highly specific tool for studying the activity of the Androgen Receptor (AR) in real-time. By monitoring GFP fluorescence in response to testosterone or other androgenic ligands, researchers can investigate AR’s role in processes related to reproductive biology, muscle development, and metabolism. The ability to modulate and measure AR activity is invaluable for exploring signaling pathways involved in androgen-dependent disorders, prostate cancer, and therapeutic research focused on androgen receptor antagonists.
This product is supplied as pre-packaged lentiviral particles only. Plasmids are not available for this product.
Additional Information
Additional Information
LipExoGen GAL4-NR System
The GAL4-NR reporter assay lentiviruses are designed with two vectors: one containing 5X UAS (upstream activator sequences) of GAL4 upstream of a reporter (GFP, RFP, Lactamase, or Firefly Luc) and downstream of an EF1α promoter-driven puromycin selection marker. The second vector expresses the GAL4 DNA binding domain (DBD) fused with the partial hinge and ligand-binding domain (LBD) of a nuclear receptor (NR), separated from the blasticidin selection marker by a P2A self-cleaving peptide. Upon ligand binding, the GAL4-DBD-NR-LBD fusion protein activates the 5X UAS reporter (e.g., GAL4-TAG (GFP)-puro), leading to GFP expression, detectable by flow cytometry and luminometry.
Although NR transcriptional activity can be detected through DNA-binding elements in cells with endogenous or exogenous receptors, assessing the specificity and function of NR family members is challenging due to their lack of DNA-binding specificity.
The LipExoGen GAL4-NR platform allows for the creation of stable cell lines for screening NR agonists or antagonists with high sensitivity, while minimizing cross-reactivity with other nuclear receptors. This system also evaluates NR interactions with coactivators or regulators in various cell types, enhancing drug discovery in vivo.
For NR suppression, the platform incorporates the activation domain (AD) of human SREBP1 or VP16, enabling reporter activity without a ligand. Upon addition of corresponding ligands, agonists, or antagonists, the GAL4-NR-LBD-VP16/AD system effectively monitors NR actions, even for receptors with weak transcriptional activity.
The system supports the study of all 48 known NRs, with customizable options for stable cell line creation, enabling efficient drug screening. High-titer lentiviral particles (third generation), VSV-G pseudotyped, are provided for transducing primary or thawed cells, ensuring effective transduction even in hard-to-transfect cells.